



peppies.com

July 11, 2026

Pharmacy Compounding Advisory Committee
c/o Takyiah Stevenson, PharmD — Designated Federal Officer
Center for Drug Evaluation and Research, U.S. Food and Drug Administration
10903 New Hampshire Avenue, Silver Spring, MD 20993

Re: Supplemental disclosure to the comment of Peppies filed July 9, 2026 (Comment Tracking Number mre-8o74-y1mr) — Docket No. FDA-2025-N-6895 (Pharmacy Compounding Advisory Committee, July 23–24, 2026)

Dear Members of the Committee:

We write to supplement our public comment of July 9, 2026 (Comment Tracking Number mre-8o74-y1mr) with a disclosure, in the interest of full transparency.

Peppies is a private, for-profit venture. Today it operates solely as an independent, cited consumer-education resource: it does not sell, promote, or facilitate the sale of any peptide, it is not affiliated with the FDA, and it makes no medical or efficacy claims. Its founder, however, is a businessman. If and when a lawful, regulated pathway for these substances exists, Peppies may choose to participate in that lawful market, as any business could.

We disclose this so the Committee can weigh our comment with full knowledge of our interest — and we want to be equally plain about what that interest is. Peppies would benefit only from a legal, tested, regulated market. It would gain nothing from the unregulated status quo our comment describes; if anything, that status quo is the harm our comment asks the agency to address. Our commercial interest and the consumer-safety concern set out in our comment therefore point in the same direction: toward a lawful, accountable channel that does not exist today.

Nothing in this disclosure changes the substance of our July 9 comment, which we reaffirm in full.

Thank you for your service, and for considering this comment.

Respectfully submitted,

A handwritten signature in blue ink, appearing to read "Ken Underwood".

Ken Underwood
Founder, Peppies, LLC
peppies.com · ken@peppies.com